Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) Chief Executive Officer Neal Walker will address investors Sept. 10 at the Cantor Global Healthcare Conference in New York as the clinical-stage …
Aclaris CEO to Detail Drug Pipeline at Cantor Conference Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) received Fast Track designation from the U.S. Food and Drug Administration for modzatinib as a potential treatment for moderate to severe lichen …
FDA Fast Track Status Advances Aclaris Lichen Planus Drug Read More WAYNE, PA — Aclaris Therapeutics Inc. (NASDAQ: ACRS) raised $40.2 million through an at-the-market stock sale after the second quarter, extending its expected cash runway through the end of 2028 …
Aclaris Raises Capital as Drug Pipeline Spending Accelerates Read More WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) outlined plans for multiple mid- and late-stage clinical milestones this year as the biotechnology company advances experimental treatments for asthma, atopic dermatitis …
Aclaris Expands Immunology Pipeline Ahead of Key Trial Data Read More WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported full results from a Phase 1a clinical trial of its ATI-052 antibody and outlined plans to advance multiple programs, including selecting …
Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline Read More WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) will present new data from its Phase 2a trial of ATI-2138 in patients with moderate-to-severe atopic dermatitis at the 2026 American Academy …
Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) has completed patient enrollment in its Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis, marking a development milestone for …
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) reported its financial results for the fourth quarter and full year of 2025 and provided updates on several clinical-stage drug development programs, …
Aclaris Reports 2025 Financial Results and Clinical Trial Updates Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) said it has initiated a randomized, placebo-controlled Phase 1b proof-of-concept trial of its investigational antibody ATI-052 in patients with asthma, as it …
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it will take center stage at two major healthcare investor conferences in February, giving Wall Street and industry watchers a fresh …
Aclaris Lines Up February Spotlight at Major Biotech Investor Conferences Read More